Blarcamesine Shows Promise in Reducing Alzheimer’s Biomarkers

Anavex Life Sciences has announced promising results from their phase 2b/3 trial investigating blarcamesine, an investigational treatment for early-stage Alzheimer’s disease. The study showed significant reductions in amyloid-ß biomarkers and a notable slowing of brain atrophy among treated patients.  The trial, which enrolled 508 participants across five countries, was a […]

Anavex Life Sciences’ Blarcamesine Shows Promise in Alzheimer’s Treatment

Anavex Life Sciences has recently announced promising results from a Phase 2b/3 clinical trial evaluating blarcamesine, an investigational drug for early Alzheimer’s disease. The study revealed significant reductions in pathological amyloid-ß levels and a marked slowdown in brain atrophy among patients treated with the drug.  The trial involved 508 participants […]